Advertisement
Letter to the Editor| Volume 29, e13-e15, April 2016

Download started.

Ok

Direct new oral anticoagulants in the emergency department: Experience in everyday clinical practice at a Swiss university hospital

Published:January 05, 2016DOI:https://doi.org/10.1016/j.ejim.2015.12.009
Direct new oral anticoagulants in the emergency department: Experience in everyday clinical practice at a Swiss university hospital
Previous ArticleObesity and breast cancer — Association even more relevant in males?
Next ArticleUtility of NT-proBNP in predicting infarct scar and left ventricular dysfunction at a chronic stage after myocardial infarction
      Since 2009, an increasing number of patients presenting to emergency departments (ED) are on anticoagulant medication with the newer direct oral anticoagulants (NOAC), such as rivaroxaban (Xarelto), apixaban (Eliquis), and dabigatran (Pradaxa). Important advantages of these agents are easier therapy management, faster onset of therapeutic effect, and an increasing range of approved indications in comparison to the classic Vitamin-K antagonists (VKA) such as warfarin and phenprocoumon (Marcoumar). Major concerns in the treatment of patients on all anticoagulant medication are bleeding events.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Chai-Adisaksopha C.
        • Hillis C.
        • Isayama T.
        • Lim W.
        • Iorio A.
        • Crowther M.
        Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials.
        J Thromb Haemost. 2015; 13: 2012-2020
        View in Article
        • Southworth M.R.
        • Reichman M.E.
        • Unger E.F.
        Dabigatran and postmarketing reports of bleeding.
        N Engl J Med. 2013; 368: 1272-1274
        View in Article
        • Harel Z.
        • Sholzberg M.
        • Shah P.S.
        • Pavenski K.
        • Harel S.
        • Wald R.
        • et al.
        Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD.
        J Am Soc Nephrol. 2014; 25: 431-442
        View in Article
        • Kumar S.
        • Danik S.B.
        • Altman R.K.
        • Barrett C.D.
        • Lip G.Y.
        • Chatterjee S.
        • et al.
        Non-VKA oral anticoagulants and antiplatelet therapy for stroke prevention in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.
        Cardiol Rev. Aug 11 2015; ([Epub ahead of print])
        View in Article
        • Held C.
        • Hylek E.M.
        • Alexander J.H.
        • Hanna M.
        • Lopes R.D.
        • Wojdyla D.M.
        • et al.
        Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial.
        Eur Heart J. 2015; 36: 1264-1272
        View in Article
        • Dans A.L.
        • Connolly S.J.
        • Wallentin L.
        • Yang S.
        • Nakamya J.
        • Brueckmann M.
        • et al.
        Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
        Circulation. 2013; 127: 634-640
        View in Article
        • Van der Hulle T.
        • Kooiman J.
        • den Exter P.L.
        • Dekkers O.M.
        • Klok F.A.
        • Huisman M.V.
        Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis.
        J Thromb Haemost. 2014; 12: 320-328
        View in Article
        • Gómez-Outes A.
        • Terleira-Fernández A.I.
        • Lecumberri R.
        • Suárez-Gea M.L.
        • Vargas-Castrillón E.
        Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
        Thromb Res. 2014; 134: 7747-7782
        View in Article
        • Granger C.B.
        • Alexander J.H.
        • McMurray J.J.
        • Lopes R.D.
        • Hylek E.M.
        • Hanna M.
        • et al.
        ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2011; 365: 981-992
        View in Article
        • Patel M.R.
        • Mahaffey K.W.
        • Garg J.
        • Pan G.
        • Singer D.E.
        • Hacke W.
        • et al.
        ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
        N Engl J Med. 2011 Sep 8; 365: 883-891
        View in Article

      Article info

      Publication history

      Published online: January 05, 2016
      Accepted: December 11, 2015
      Received: December 3, 2015

      Identification

      DOI: https://doi.org/10.1016/j.ejim.2015.12.009

      Copyright

      © 2015 European Federation of Internal Medicine. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX